News Conference News ACC 2025 Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years L.A. McKeown March 30, 2025
News Conference News TCT 2023 Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials Michael O'Riordan October 24, 2023
News Daily News ‘Functional’ SYNTAX Score May Hone PCI, CABG Choices in Multivessel Disease Michael O'Riordan September 13, 2023
News Features Major TAVI Studies Have ‘Methodological Issues,’ INTEGRITTY Group Contends Michael O'Riordan January 06, 2023
Presentation ACC 2022 5-Year Incidence, Outcomes and Predictors of Structural Valve Deterioration of Transcatheter and Surgical Aortic Bioprostheses: Insights from the CoreValve US Pivotal and SURTAVI Trials Presenter: Michael J. Reardon April 04, 2022
News Conference News ACC 2022 Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years Michael O'Riordan April 04, 2022
News Daily News Making Sense of MI: EXCEL and SYNTAX Tackle Event Definitions Michael O'Riordan September 28, 2020
News Daily News SAVR After Failed TAVR: Rare and Risky, Registry Study Finds Yael L. Maxwell June 10, 2020
News Conference News AHA 2017 DACAB: Ticagrelor and Aspirin Improve SVG Patency at 1 Year Post-CABG vs Monotherapy Yael L. Maxwell November 12, 2017